[On pathogenesis of purpura pigmentosa progressiva (with particular reference to adalin-induced purpura)].
D000328:Adult; D002087:Butyrates / Q000009:adverse effects*; D003872:Dermatitis / Q000209:etiology; D003877:Dermatitis, Contact / Q000209:etiology; D003937:Diagnosis, Differential; D003875:Drug Eruptions / Q000209:etiology*; D005260:Female; D006801:Humans; D006968:Hypersensitivity, Delayed; D006969:Hypersensitivity, Immediate; D006993:Hypnotics and Sedatives / Q000009:adverse effects*; D007154:Immune System Diseases; D007868:Leg Dermatoses / Q000209:etiology; D008297:Male; D010858:Pigmentation / Q000187:drug effects; D010859:Pigmentation Disorders / Q000209:etiology; D011693:Purpura / Q000139:chemically induced / Q000175:diagnosis; D012871:Skin Diseases / Q000209:etiology; D013684:Telangiectasis / Q000209:etiology; D014508:Urea / Q000009:adverse effects*
D002087:Butyrates; D006993:Hypnotics and Sedatives; D014508:Urea
Zum Formenkreis der Purpura pigmentosa progressiva (unter besonderer Berücksichtigung der Adalin-Purpura)